Therefore, more studies are needed to determine the precision of combining CXCR3 expression, tumor-infiltrating T-cell isoforms, and anti-PD-1/PD-L1 treatment response in patients with cervical cancer. The gene discussed is CXCR3; the disease is cervical carcinoma.